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H eart failure is one of the most common causes of death in heart disease patients.  Despite signifi-
cant improvements in pharmacological and interven-
tional treatment for heart failure,  current treatment is 
palliative and cannot restore the cardiac function or 
maintain normal heart function over the long term 
[1 , 2].  In the case of end-stage heart failure,  heart 
transplantation is currently the only available treat-
ment.  However,  for many patients,  transplantation is 
not a viable option given the strict criteria for eligibility 
and the long waiting period due to the limited numbers 
of heart donors in Japan [3].
In recent years,  interest has inclined more towards 
myocardial regeneration with the application of stem 
cells [4 , 5].  Clinical trials have used various types of 
autologous transplanted cells,  such as adipose tissue- 
derived mesenchymal stem cells [6],  bone marrow- 
derived mesenchymal stem cells [7 , 8],  and cardio-
sphere-derived cells (CDCs) [9],  and achieved an 
increase in viable myocardial tissue and a decrease in 
infarct size.  However,  many questions remain unre-
solved,  and for now,  no cell therapy has been unequiv-
ocally shown to be effective for the treatment of heart 
diseases.  Therefore,  new strategies have been devel-
oped in order to improve the potency of current stem 
cell therapies.
In this review,  we provide an overview of the differ-
ent cell types that have been used in regenerative thera-
pies to treat heart diseases.  We also discuss promising 
strategies to improve the outcome of stem cell therapies.
Stem Cell-Based Therapies for the Treatment of 
Heart Disease
Several types of cells have been used in cell therapy 
and are beneficial for improving cardiac function,  
mainly in cases of ischemic heart disease.  Stem cell-
based therapy has the ability to activate endogenous 
regenerative processes,  which include the recruitment 
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of resident stem and progenitor cells and the promotion 
of cardiomyocyte proliferation [10].  Pluripotent stem 
cells seem to be an appropriate candidate due to their 
proliferative properties and their ability to differentiate 
into various cell type,  including cardiomyocytes [11].
Skeletal myoblasts. In the field of cardiac regen-
eration,  skeletal myoblasts were the first cell type to be 
tested both in pre-clinical and clinical trials in patients 
with ischemic heart disease.  The first effective trans-
plant of skeletal myoblasts into the damaged human 
heart was performed in 1994 [12].  However,  in most of 
the clinical trials using skeletal myoblasts,  a high inci-
dence of ventricular arrhythmias was detected in 
patients treated with the cells [13 , 14].
Bone marrow-derived stem cells. Bone marrow- 
derived stem cells are one class of multipotent stem cells 
that have attractive properties.  Bone marrow contains 
several subpopulations of cells with the ability to trans- 
differentiate into both myocardial and vascular cells 
[15].  Although patients randomized to receive skeletal 
myoblasts in the Myoblast Autologous Grafting in 
Ischemic Cardiomyopathy (MAGIC) trial had a higher 
incidence of ventricular arrhythmias,  patients who 
received transplantation of bone marrow mononuclear 
cells did not show an increased rate of arrhythmias [16].  
The limited survival of implanted stem cells in trials 
using bone marrow mononuclear cells and the fact that 
the favorable effects of adult stem cells are mediated by 
mechanisms other than direct cardiomyocyte differenti-
ation might account for this favorable safety profile.
Mesenchymal stem cells (MSCs). MSCs,  which 
reside in the stroma of bone marrow,  are found in bone 
marrow,  muscle,  adipose tissue,  and skin [17].  MSCs 
can transdifferentiate into cardiomyocytes under certain 
condition,  such as in co-cultures with cardiomyocytes 
[18].  They also can be induced to differentiate into 
endothelial cells by culturing with vascular endothelial 
growth factors (VEGF) [19].  Notably,  MSCs are con-
sidered to be immune-privileged and exhibit immuno-
suppressive properties,  permitting them to be applied in 
an allogeneic setting [20].
Cardiac progenitor cells (CPCs)/Cardiosphere-
derived cells (CDCs). CPCs or CDCs are believed to 
reside in the myocardium [21].  CDC populations may 
offer major advantages over extracardiac cell sources 
because the cardiac progenitors differentiate along both 
the cardiomyocytic and vascular lineages,  which sur-
vive well in the myocardial environment.  CDCs consti-
tute a candidate pool of such cardiac stem cells that 
comprise a heterogeneous population of cardiac cells,  
including a potentially clonogenic stem cell subpopula-
tion.  Several basic studies have reported the validity of 
CPC or CDC injection for inducing angiogenesis and 
stimulating endogenous CPCs to promote regeneration 
[22 , 23].  However,  the main limitation in using such 
injections is the decreasing number of CPCs or CDCs 
with age [24] and their subsequent reduced potency to 
regenerate the myocardium [25].  Results from the 
CADUCEUS trial after a one-year follow-up described 
a subtle enhancement in the viability of cardiac muscle 
without benefit to cardiac function [9].  Although a 
meta-analysis of several cardiac clinical trials showed 
that cell therapy provided no benefits in terms of 
improving left ventricular function after myocardial 
infarction (MI) [26],  cell therapy trials using autolo-
gous CDCs for congenital heart disease showed 
improvements in ventricular function by reverse 
remodeling,  improved heart failure status [27 , 28],  and 
reduced late complications [29].  These experimental 
studies have suggested that the decline of cardiomyo-
cyte replication might be associated with the absolute 
loss of intrinsic progenitor cells or reduced potential of 
preexisting mature myocyte proliferation during heart 
development.
Embryonic stem cells (ESCs). ESCs are derived 
from the inner cell mass of the blastocyst and have the 
ability to discriminate into cell types of all three germ 
layers (endoderm,  mesoderm,  and ectoderm) [30].  
Cardiomyocytes are known to originate from the meso-
derm layer,  and many different in vitro protocols have 
been established to induce cardiomyogenic differentia-
tion of ESCs despite the challenges of generating large 
quantities of pure and mature cardiomyocytes [31].  In 
2018,  the phase I clinical ESCORT trial was performed;  
this was the first trial to apply human ESC-derived 
cardiac progenitors embedded onto a fibrin matrix for 
the treatment of patients suffering from severe heart 
failure [32].  Nevertheless,  clinical trials of these cells 
have been challenging due to ethical issues,  genetic 
variability,  the risk of immune rejection,  and potential 
tumorigenicity [33].
Induced pluripotent stem cells (iPSCs). iPSCs 
were developed in 2006 from mouse fibroblasts by the 
retroviral introduction of four defined transcriptional 
factors known as Yamanaka factors,  namely,  c-Myc,  
octamer-binding transcription factor 3/4 (Oct3/4),  sex 
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determining region Y-box 2 (Sox-2),  and kruppel-like 
factor 4 (Klf4) [34].  These iPSCs have the full potential 
for cardiac regeneration,  and iPSC-derived cardiomyo-
cytes have several practical characteristics of cardiac 
cells,  such as contractility,  spontaneous beating,  and 
ion channel expression using cytokines such as activin 
A and BMP4 [35].  The addition of chemical com-
pounds that inhibit Wnt signaling was also shown to 
enhance the cardiac myocyte differentiation efficiency 
markedly [36].  However,  functional analyses of 
iPSC-derived cardiomyocytes revealed that these cells 
are immature and more related to embryonic rather 
than adult cardiomyocytes [37].  Also,  various studies 
described genomic instabilities in iPSC lines that could 
be actual risk factors for adverse effects,  including 
malignant outgrowth [38].
Potential Mechanisms of Stem Cell Therapy in 
Heart Failure
Recent studies have revealed that stem cell trans-
plantation stimulates the endogenous cardiac repair 
process via paracrine signaling,  direct cell-to-cell inter-
action,  and/or transfer of microRNAs from exosomes 
that influence the transcriptional activity of host cells 
[39].  Classically,  it is believed that an ideal stem cell 
should differentiate into cardiomyocytes that integrate 
both mechanically and electrically with innate myo-
cytes.  However,  data obtained from numerous studies 
led to the conclusion that the paracrine effect is the 
fundamental mechanism that mediates the beneficial 
effects of stem cell therapy [40].
Today,  it is generally accepted that stem cells release 
factors such as cytokines,  chemokines,  and growth 
factors that affect the cellular environment.  For exam-
ple,  stem cells reconstruct the myocardial vascular sys-
tem by secreting VEGF,  basic fibroblast growth factor 
(bFGF),  and insulin growth factor-1 (IGF-1) as proan-
giogenic factors.  IGF-1 also has the potency to inhibit 
the death of cardiomyocytes by apoptosis.  Cells com-
municate with each other via released microparticles 
enriched in pre-microRNAs and exosomes in their cel-
lular environment.  Exosomes are membrane vesicles 
(40-100 nm in diameter) formed by endocytosis.  Barile 
et al.  showed that exosomes isolated from mouse CPCs 
protected H9C2 from oxidative stress by inhibiting 
caspase 3/7 activation in vitro while reducing cardio-
myocyte apoptosis in a mouse model of myocardial 
ischemia in vivo [41].  Timmers et al.  showed that injec-
tion of media conditioned by MSCs that contained the 
active component of exosomes reduced infarct size and 
improved cardiac function in a pig ischemic model [42].  
A recent report claims that MSC-extracellular vesicles 
are sufficient to improve angiogenesis and exert a thera-
peutic effect on MI; the pro-angiogenesis effect of these 
vesicles might be associated with an miR-210-Efna3- 
dependent mechanism [43].  Increasing evidence sug-
gests that exosomes may act as a vector of genetic infor-
mation,  and mRNAs carried by exosomes can be trans-
lated into proteins in the target cell.
Improvement Strategies to Boost the Potency 
of Stem Cells
A growing number of phase I and II clinical trials 
have proven the feasibility and safety of stem cell ther-
apy [44].  Several meta-analyses and systemic reviews 
reported a slight but significant improvement in heart 
function of between 2-5% [44 , 45]; however,  a meta- 
analysis of several cardiac clinical trials showed that cell 
therapy provided no benefit in terms of left ventricular 
function after MI [26].  This limited outcome of stem 
cell-based clinical trials necessitates the development of 
novel strategies to boost the efficiency of stem cells for 
cardiac repair.  Two major concepts must be considered 
in generating the next generation of stem cell therapy:  
1) pharmacological preconditioning and 2) genetic 
stem cell modification approaches.  Using these tech-
niques,  numerous stem cell properties can be 
addressed,  including engraftment,  survival,  paracrine 
activity,  angiogenetic potential,  and differentiation 
capacity.
Pharmacological preconditioning. Stem cell-
based therapy is hindered by limited transplantation 
efficiency,  and researchers have aimed to solve this 
problem with appropriate cell modification.  
Pharmacological preconditioning represents a conve-
nient and cost-effective technique to stimulate the 
regenerative activity of stem cells.  Alteration of stem 
cell culture conditions,  cytokines and drug pretreat-
ments are among the possible strategies.  The use of 
hypoxia-conditioned media for the production of CPC 
or CDC sheets resulted in cells that secreted mRNAs 
and angiogenetic factors,  which in turn led to better 
performance in cardiac function and a reduction of 
fibrosis [46 , 47].  Pretreatment of MSCs with atorvasta-
tin improved the cell survival through induction of MSC 
autophagy by activating the AMPK/mTOR and MEK/
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ERK pathways [48].  A recent report indicated that pre-
treatment of CDCs with resveratrol increased capillary 
density and decreased cardiomyocyte apoptosis in the 
peri-ischemic myocardium by the upregulation of 
VEGF and stromal derived factor (SDF)-1α [49].  As 
these cells exert their therapeutic effects on damaged 
tissue mainly by paracrine signaling,  drug pretreatment 
was applied to promote their secretion activity [50].
Genetic stem cell modification. Genetic modifi-
cation is highly desirable as another powerful technique 
to boost stem cell efficiency.  Compared with non- 
genetic based pre-conditioning,  genetic tools for spe-
cific perturbation of endogenous gene expression are 
usually applied to induce prolonged effects of stem cell 
activity.  In general,  three main strategies of genetic 
modification can be applied for stem cell therapy:  
1) protein overexpression by DNA delivery,  2) gene 
silencing by RNAi [51],  and 3) gene editing using 
TALENs or CRISPR/Cas9.
Overexpression of therapeutic factors,  including 
VEGF,  SDF-1,  FGF,  and IGF-1,  can be induced using 
DNA-based modifications.  IGF-1 overexpression has 
been utilized to positively influence the paracrine signa-
ture of human cardiac stem cells.  Cardiac function was 
slightly improved with IGF-1-modified stem cells four 
weeks after MI,  and apoptotic events in the infarcted 
myocardium were less frequent in stem cells engineered 
to overexpress IGF-1 [52].  Mice treated with SDF-1α-
modified cardiac stem cells demonstrated a significant 
improvement of ejection fraction and reduction of scar 
area compared to unmodified control cells.  
Interestingly,  these cells were shown to induce a two-
fold increase in proliferating cardiomyocytes [53].
Synthetic transcriptional activators derived from the 
CRISPR/Cas9 system are emerging as powerful new 
tools for activating the endogenous expression of target 
genes [54].  These synthetic constructs,  generated by 
tethering transcriptional activation domains to a nucle-
ase-dead Cas9(dCas9),  can be directed to the promot-
ers or enhancers of endogenous target genes by single- 
guide RNAs (sgRNAs) to activate transcription.  CDC 
populations may offer major advantages over extracar-
diac cell source,  because these cells exhibit a balanced 
profile of paracrine factor production and provide the 
greatest functional benefit in MI [55]; however,  the 
reduced differentiation potential of CDCs to develop 
into a functional population of cardiomyocytes has 
always been a significant setback.  If we could boost the 
cardiomyogenic efficiency of CDCs to develop into a 
large population of cardiomyocytes by the intrinsic acti-
vation of cardio-specific differentiation factors using a 
CRISPR/dCas9 gene transcriptional enhancement sys-
tem,  this approach could potentially overcome the pit-
falls of the previous cardiac regeneration efforts by 
achieving a large population of efficient cardiomyo-
cytes.
Conclusion
The limited endogenous degree of cardiac regenera-
tion is insufficient to compensate for the massive loss of 
cardiomyocytes occurring after acute and chronic heart 
failure.  The transplantation of stem cells has emerged as 
a new approach to restore damaged myocardial tissue;  
however,  the extent of the benefits of stem cell therapy 
is still controversial.  Therefore,  a deeper understand-
ing of endogenous reparative mechanisms,  as well as 
their interactions with stem cells,  is needed.
Many groups are currently investigating various 
avenues of stem cell optimization,  such as the use of 
genetic manipulations,  or of cell preconditioning using 
drugs or environmental stressors,  to increase angiogen-
esis,  enhance survival pathways,  and boost the pro-
moters to differentiate into effective cardiomyocytes.  
The potential for optimizing stem cell therapy using 
preconditioning,  genetic modification,  or other ex vivo 
manipulated stem cells will significantly propel this type 
of therapy forward and provide invaluable information 
on stem cell biology.
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